Next-Generation Sequencing in Diagnostic Pathology

Abstract

Interrogation of tissue informs on patient management through delivery of a diagnosis together with associated clinically relevant data. The diagnostic pathologist will usually evaluate the morphological appearances of a tissue sample and, occasionally, the pattern of expression of a limited number of biomarkers. Recent developments in sequencing technology mean that DNA and RNA from tissue samples can now be interrogated in great detail. These new technologies, collectively known as next-generation sequencing (NGS), generate huge amounts of data which can be used to support patient management. In order to maximize the utility of tissue interrogation, the molecular data need to be interpreted and integrated with the morphological data. However, in order to interpret the molecular data, the pathologist must understand the utility and the limitations of NGS data. In this review, the principles behind NGS technologies are described. In addition, the caveats in the interpretation of the data are discussed, and a scheme is presented to “classify” the types of data which are generated. Finally, a glossary of new terminology is included to help pathologists become familiar with the lexicon of NGS-derived molecular data.

Long non‑coding RNA HOXA‑AS2 promotes the expression levels of hypoxia‑inducible factor‑1α and programmed death‑ligand 1, and regulates nasopharyngeal carcinoma progression via miR‑519

“…Continued advances in genomics and transcriptomics have accelerate the discovery and emergence of potential biomarkers of various diseases ( 25 ). Furthermore, molecular therapies based on these key genes or pathways are becoming increasingly important in clinical therapy.…”

High Genetic Diversity and No Evidence of Clonal Relation in Synchronous Thyroid Carcinomas Associated with Hashimoto’s Thyroiditis: A Next-Generation Sequencing Analysis

“…NGS is a unique tool that can demonstrate the complex mutational profile in malignancies from clinical samples and also enables the analysis of DNA from archived FFPE tumor tissues, provided that the tissue sample is representative and the quality of the isolated genomic DNA is preserved [18,19]. Both diagnostic and predictive indications have been increasingly reported, and NGS-based thyroid cancer testing has become generally available.…”

Immunohistochemistry in screening for heritable colorectal cancer: what to do with an abnormal result

“…The current 4‐antibody IHC approach to screening for LS in CRC is largely robust and may be streamlined by adopting an initial 2‐antibody strategy. Recent advances in direct tumour DNA analysis with the advent of next generation sequencing (NGS) show great potential for LS screening . NGS allows simultaneous evaluation of MSI and multiple genes including MLH1 , MSH2 , PMS2 , MSH6 and EPCAM , effectively collapsing screening into a single‐step process .…”